MedTrace Logo

Use of Oral Contraceptives (OCs) Containing Dienogest and Risk of Venous Thromboembolism

NCT00523614 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3400

Last updated 2010-03-23

Study results available
· View outcomes & findings →

Summary

The objective of this study is to compare the risk of venous thromboembolism (VTE) of oral contraceptives with non-use, focusing specifically on Valette® compared to other users of low estrogen dose combined oral contraceptives.

Conditions

  • Venous Thromboembolism

Sponsors & Collaborators

  • Bayer

    collaborator INDUSTRY

  • Center for Epidemiology and Health Research, Germany

    lead OTHER

Principal Investigators

  • Juergen C Dinger, MD, PhD · Center for Epidemiology and Health Research

Eligibility

Min Age
15 Years
Max Age
49 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-07-31
Completion
2008-06-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00523614 on ClinicalTrials.gov